Libraries of 2β-(N-substituted piperazino)-5α-androstane-3α, 17β-diols: chemical synthesis and cytotoxic effects on human leukemia HL-60 cells and on normal lymphocytes.
Libraries of steroid derivatives with two levels of molecular diversity were prepared to optimize the antiproliferative activity on leukemia HL-60 cells by first varying the amino acid (AA) at R(1) (libraries A, B, C, and D: with 45, 45, 20, and 20 members, respectively) and, subsequently, the capping group at R(2) (library E: 168 members). The screening of these aminosteroids revealed interesting structure-activity relationships. In library A, the compounds bearing a tetrahydroisoquinolone residue as the first element of diversity showed potent cytotoxicity, principally when isovaleric or cyclohexyl acetic acid was used as a capping group (>40% of cell growth inhibition at 1 μM). In library B, the phenylalanine (Phe) derivatives bearing a cyano group induced a higher growth inhibition than the other Phe derivatives. The screening of library C indicated the increase of hydrophobicity of proline (Pro) seems to preserve the cytotoxic effect achieved by the lead compound. However, the synthesis of structural Pro variants (library D) clearly shows weaker activities when compared to L-Pro building blocks. Finally, by incorporating some of the most active AA of libraries A-D in library E, we observed that the amide coupling functionality gave stronger cytotoxic activity compared to the corresponding sulfonamides or benzylamines. Six of the most active amide derivatives (E-37P, E-41P, E-42P, E-46P, E-48F, and E-12T) were selected and IC(50) determined on HL-60 cells as well as on normal human lymphocytes. Among this series of new anticancer agents, good to high selectivity indices (SI = IC(50) (lymphocytes)/IC(50) (HL-60 cells) = 5 - 55) were obtained.
Roy
Jenny
J
Laboratory of Medicinal Chemistry, Endocrinology and Genomic Unit, CHUQ-(CHUL) Research Center, 2705 Laurier Boulevard, Quebec, QC, G1V 4G2, Canada.
Maltais
René
R
Jegham
Hajer
H
Poirier
Donald
D
D015113:Androstane-3,17-diol / Q000031:analogs & derivatives / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity*; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D018922:HL-60 Cells; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects*; D054852:Small Molecule Libraries / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity*
D054852:Small Molecule Libraries; D015113:Androstane-3,17-diol
J Comb Chem. 2000 Nov-Dec;2(6):604-14
11126290
J Comb Chem. 2007 May-Jun;9(3):347-58
17441773
J Clin Invest. 2000 Jan;105(1):3-7
10619854
Bioorg Med Chem. 2001 Dec;9(12):3101-11
11711285
Life Sci. 2006 Sep 27;79(18):1692-701
16824549
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
Leuk Lymphoma. 2007 Mar;48(3):605-15
17454606
J Comb Chem. 2003 Jul-Aug;5(4):429-40
12857111
Leukemia. 2004 Aug;18(8):1332-9
15190258
Mini Rev Med Chem. 2006 Jan;6(1):37-52
16457631
ChemMedChem. 2006 Nov;1(11):1249-59
16986200
J Comb Chem. 2004 Jul-Aug;6(4):443-56
15244402
Bioorg Med Chem. 2008 May 1;16(9):5062-77
18375126
Leuk Res. 1999 Apr;23(4):369-72
10229323
J Med Chem. 1997 May 23;40(11):1668-81
9171876
Mol Divers. 2005;9(1-3):67-79
15789554
Clin Ther. 2009;31 Pt 2:2349-70
20110045
Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15
18056932